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In Brief
Duan et al. show that limited regeneration
of retinal ganglion cell (RGC) axons
following transection reflects preferential
survival and selective regeneration of one
subset, aRGCs. aRGCs selectively
express osteopontin and IGF1 receptor;
administered together, osteopontin and
IGF1 promote aRGC regeneration.
Neuron
ArticleSubtype-Specific Regeneration of Retinal
Ganglion Cells following Axotomy: Effects
of Osteopontin and mTOR Signaling
Xin Duan,1,3 Mu Qiao,1,3 Fengfeng Bei,2,3 In-Jung Kim,1,5 Zhigang He,2,4,* and Joshua R. Sanes1,4,*
1Department of Molecular and Cellular Biology, Center for Brain Science, Harvard University, 52 Oxford Street, Cambridge, MA 02138, USA
2F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Avenue,
Boston, MA 02115, USA
3Co-first author
4Co-senior author
5Present address: Department of Ophthalmology, Yale University School of Medicine, New Haven, CT 06510, USA
*Correspondence: zhigang.he@childrens.harvard.edu (Z.H.), sanesj@mcb.harvard.edu (J.R.S.)
http://dx.doi.org/10.1016/j.neuron.2015.02.017SUMMARY
Inmammals, few retinal ganglion cells (RGCs) survive
following axotomy, andeven fewer regenerate axons.
This could reflect differential extrinsic influences
or the existence of subpopulations that vary in their
responses to injury. We tested these alternatives by
comparing responses ofmolecularly distinct subsets
of mouse RGCs to axotomy. Survival rates varied
dramatically among subtypes, with alpha-RGCs
(aRGCs) surviving preferentially. Among survivors,
aRGCs accounted for nearly all regeneration
following downregulation of PTEN, which activates
the mTOR pathway. aRGCs have uniquely high
mTOR signaling levels among RGCs and also selec-
tively express osteopontin (OPN) and receptors for
the insulin-like growth factor 1 (IGF-1). Administration
of OPN plus IGF-1 promotes regeneration as effec-
tively as downregulation of PTEN; however, regener-
ation is still confined to aRGCs. Our results reveal
dramatic subtype-specific differences in the ability
of RGCs to survive and regenerate following injury,
and they identify promising agents for promoting
axonal regeneration.
INTRODUCTION
Regeneration following injury to the mammalian brain or spinal
cord is notoriously poor: few survivors extend axons beyond
the injury site (Ramon y Cajal, 1928), and in some cases, many
of the axotomized neurons die (Mansour-Robaey et al., 1994;
Conta Steencken et al., 2011). Limited regeneration can be
explained in at least two different ways. First, non-genetic
differences among neurons could account for differences in
outcome—for example, stochastic variation, history of activity,
or proximity to environmental cues that modulate growth. Alter-
natively or in addition, distinct subpopulations within a seemingly1244 Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc.homogeneous population could regenerate preferentially, owing
to preexisting qualities that improve their lot. Distinguishing
among these and other alternatives is important both in guiding
searches for protective factors and in assessing interventions
designed to enhance regeneration.
Here, we analyzed retinal ganglion cells (RGCs) to address
this issue. All visual information is conveyed from the eye to
the brain by RGC axons, which run though the optic nerve to ret-
inorecipient areas such as the superior colliculus and lateral
geniculate nucleus. Although all RGCs share numerous attri-
butes, they can be divided into 30 distinct subpopulations,
on the basis of morphological, physiological, and molecular
criteria (Masland, 2012; Sanes and Masland, 2015). After dam-
age to the mouse optic nerve, >80% of RGCs die, and <1% of
the survivors extend axons past the site of damage (Mansour-
Robaey et al., 1994; Park et al., 2008). Regeneration of a
substantial number of RGC axons can be elicited, however, by
manipulations of the neurons themselves or the environment
through which they grow (Aguayo et al., 1991; Benowitz and
Popovich, 2011; Liu et al., 2011; Maier and Schwab, 2006;
Park et al., 2008; Smith et al., 2009; Sun et al., 2011). Thus,
one can ask whether specific subsets of RGCs differ in their abil-
ities to survive following nerve crush and/or regenerate axons
following treatment.
In the first part of this study, we assessed the survival of 11
RGC subtypes after transection of the optic nerve in mice. Sub-
types differed dramatically in susceptibility to damage, with the
largest RGC types, alpha-RGCs (aRGCs), surviving preferentially
but not exclusively. We then promoted regeneration by sup-
pressing expression of PTEN, which acts, at least in part, by
enhancing mTOR activity (Jaworski et al., 2005; Kim et al.,
2009; Park et al., 2008; Zukor et al., 2013). We found that
aRGCs accounted for nearly all of the regenerating axons in
this paradigm.
On the basis of these results, we sought features of aRGCs
that might account for their regenerative ability and found three:
they have high endogenous levels of mTOR activity, they selec-
tively express a secreted phosphoprotein, osteopontin (OPN)
(Bellahce`ne et al., 2008; Wang and Denhardt, 2008), which
is capable of stimulating mTOR activity (Ahmed and Kundu,
2010), and they selectively express receptors for insulin-like
growth factor 1 (IGF-1), which promotes the regeneration of
some neuronal types (Dupraz et al., 2013). Ectopic expression
of OPN in combination with IGF-1 promotes regeneration
of aRGCs as effectively as PTEN suppression. Together, our
work identifies a neuronal-intrinsic factor that can promote
regeneration and provides a strategy to identify additional regen-
eration-promoting factors.
RESULTS
Differential Survival of RGC Subtypes
We used immunohistochemical and transgenic approaches
to mark molecularly distinct subsets of RGCs in mice: (1)
There are four groups of ON-OFF direction-selective RGCs
(ooDSGCs), each tuned to motion in a single direction: ventral,
dorsal, nasal, and temporal. Antibodies to the neuropeptide
cocaine- and amphetamine-regulated transcript (CART) label
all four groups (Kay et al., 2011), while a transgenic line, HB9-
GFP, labels the subset tuned to ventral motion (Trenholm
et al., 2011). (2) W3-RGCs are labeled with yellow fluorescent
protein (YFP) in the TYW3 mouse line (Kim et al., 2010). W3-
RGCs are among the smallest RGCs in terms of soma size and
dendritic diameter and are among the most numerous RGCs.
They comprise at least two populations: W3B, which are motion
sensitive but not direction selective, and W3D, which remain
physiologically uncharacterized (Zhang et al., 2012). (3) Anti-
bodies to melanopsin label M1- and M2-RGCs, two subsets of
intrinsically photosensitive RGCs that can be distinguished by
the sublaminae of the inner plexiform layer within which their
dendrites arborize (Berson et al., 2010; Ecker et al., 2010). (4)
The RGCs with the largest somata are aRGCs. In mice, they
comprise at least three subtypes, which differ in physiological
properties as well as dendritic stratification (Estevez et al.,
2012; Pang et al., 2003; Schubert et al., 2005; van Wyk et al.,
2009; Vo¨lgyi et al., 2005). We recently generated and character-
ized a mouse line in which Cre recombinase is inserted into the
locus encoding a potassium channel modifier, kcng4. When
crossed to a reporter line (Buffelli et al., 2003), subsets of bipolar
cells and RGCswere YFP positive in double-transgenic offspring
(Kcng4-cre;Thy1-stop-YFP line 1; called Kcng4-YFP here) (Duan
et al., 2014). Further analysis revealed that the labeled RGCs had
large somata and dendrites and were rich in a neurofilament-
associated epitope, SMI32 (Figure S1). These features identified
them as aRGCs (Berson, 2008; Peichl, 1991). Morphological and
physiological analysis revealed that labeled RGCs included all
three types of aRGCs, and no other RGCs (Figure 1B; M.Q.,
X.D., J.R.S., B. Krieger, and M. Meister, unpublished data).
Thus, the Kcng4-cre line provides selective genetic access to
aRGCs. Together, these markers allowed us to assay the sur-
vival of 11 RGC subtypes (4 ooDSGCs, 2 W3-RGCs, 3 aRGCs,
and 2 melanopsin-positive RGCs).
We crushed the optic nerves of wild-type or transgenic mice
and then assessed RGC survival 14 days post crush (dpc).
Consistent with previous reports (Park et al., 2008), 20% of
RGCs survived, as assessed by staining for class III beta-tubulin
(Tuj1), a pan-RGC marker (Figures 1A and 1C). The survival rate
varied greatly among RGC subtypes. More than 80% of theaRGCs (Kcng4-YFP RGCs) and more than 70% of the M1-
RGCs survived, whereas few if any M2-RGCs or ooDSGCs
(HB9-GFP and CART+ RGCs) survived (Figures 1A–1C). Survival
of W3-RGCs was intermediate (10%). Examination of Kcng4-
YFP retinal cross-sections, in which the three aRGC subtypes
can be distinguished by dendritic lamination, indicated that all
three subtypes survived (Figure 1B). As a consequence, aRGCs
and M1-RGCs, which comprise 6% and 3% of all RGCs in
the normal retina, respectively, accounted for 23% and 11% of
surviving RGCs by 14 dpc (Figure 1E).
To assess whether the apparently preferential survival of
aRGCs represented a delayed cell loss, we examined animals
after 2 additional weeks (28 dpc). Although 10% of the RGCs
were lost between 14 and 28 dpc, aRGCs and M1-RGCs were
still preferentially spared and constituted 25% and 15% of
all surviving RGCs, respectively (Figures 1D and 1E). Thus,
aRGCs and M1-RGCs survive preferentially but not exclusively
following nerve crush.
Selective Regeneration of aRGCs
Next, we compared the ability of RGC subtypes to extend axons
following injury. To promote regeneration, we injected an
adeno-associated virus (AAV) encoding a previously validated
short hairpin RNA directed against PTEN (shPTEN) (Zukor
et al., 2013), a negative regulator of mTOR signaling. We used
immunostaining for a phosphorylated form (Ser235/236) of ribo-
some protein S6 (pS6) to assay the efficacy of shPTEN, on the
basis of previous studies showing that pS6 provides a reliable
estimate of mTOR activity (Laplante and Sabatini, 2012; Park
et al., 2008). Levels of pS6 were increased in 60% of RGCs
in optimally infected areas by 2 weeks after infection with AAV-
shPTEN (Figure 2A). Thus, AAV infects, and PTEN restricts
mTOR signaling in, most if not all RGC subtypes. A control
AAV (AAV-GFP) infected a similar fraction of RGCs but had no ef-
fects on pS6. AAV-shPTEN had no detectable effect on retinal
structure or integrity (data not shown).
To assess regeneration, we crushed the optic nerve in Kcng4-
YFP, HB9-GFP, and TYW3 mice 2 weeks after AAV-shPTEN
administration, then analyzed retina and optic nerve 14 dpc.
Selective survival of aRGCs following depletion of PTEN was
similar to that observed in control retinas after crush (Figure S2A
compared with Figure 1A). Regeneration was detected by count-
ing YFP- or GFP-positive axons in longitudinal sections through
the optic nerves. We observed substantial regeneration of aRGC
axons but no detectable regeneration of ooDSGC or W3-RGC
axons (Figure 2B).
To visualize all regenerating axons, we injected the antero-
grade tracer cholera toxin subunit B (CTB) into the retina 2 to
3 days before sacrifice. In all lines, approximately 150 axons
per retina regenerated at least 0.5 mm past the crush site, ac-
counting for 2.5% of surviving RGCs (Figures 2C and 2D).
Importantly, >90% of the CTB-positive axons in the Kcng4-
YFP retina were also YFP positive (Figure 2D). No markers
were available to label M1-RGC axons, but the near complete
overlap of CTB- and YFP-positive axons in the Kcng4-YFP line
suggests that few if anyM1-RGCs or other RGC subtypes regen-
erate. Thus, aRGC account for the vast majority of the regener-
ating axons after downregulation of PTEN.Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc. 1245
Figure 1. Differential Survival of RGC Sub-
types after Axotomy
(A) Whole-mount views of retinas. (Top) Retina
labeled with antibody Tuj1, which marks all RGCs.
(Bottom) Retinas from Kcng4-YFP, TYW3, and
HB9-GFP mice, in which aRGCs, W3-RGCs, and
ooDSGCs, respectively, are labeled. The scale bar
represents 50 mm.
(B) Retinal sections labeled with anti-melanopsin
in wild-type mice to label M1 and M2 cells
and YFP in Kcng4-YFP mice to label aRGCs.
Numerals 1 and 2 indicate M1- and M2-RGCs,
which can be distinguished by dendritic lamina-
tion; only M1-RGCs survive. Numerals 3 to 5
indicate examples of ON-, OFF-transient, and
OFF-sustained aRGCs, which can be distin-
guished by dendritic lamination; all three survive
axotomy. The scale bar represents 20 mm.
(C and D) Fraction of RGCs of each subtype that
survive axotomy at 14 dpc (C) or 28 dpc (D); data
from preparations such as those shown in (A) and
(B). n = 2 or 3 retinas per type.
(E) Fraction of all RGCs comprised by each sub-
type in intact retina, 14 dpc, and 28 dpc.
See also Figure S1.aRGCs Have High mTOR Activity and Are Rich in OPN
In the adult retina, 10% of RGCs are stained intensely with
anti-pS6 and therefore have high mTOR activity (Park et al.,
2008). We asked whether the pS6-rich cells are aRGCs. In initial
studies, we found variable pS6 levels in RGCs of adult mice
(data not shown). We reasoned that neuronal activity, which is
known to stimulate phosphorylation of pS6 (Knight et al.,
2012), contributed to this variability. We therefore dark-adapted
mice overnight to decrease activity of RGCs, then stained ret-
inas of Kcng4-YFP mice for pS6. In dark-adapted retinas,
6% of RGCs were clearly pS6 rich, and the others were not
detectably pS6 positive (Figure 3A). The pS6-rich RGCs were
aRGCs: >90% of Kcng4-YFP+ RGCs neurons were rich in
pS6, and >85% of pS6-rich neurons were YFP+ (Figure 3B).1246 Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc.In contrast, few if any M1-RGCs were
pS6 rich (data not shown).
mTOR acts through two signaling com-
plexes called mTORC1 and mTORC2
(Laplante and Sabatini, 2012). Phosphor-
ylation of S6 is downstream of mTORC1,
indicating that mTORC1 activity is
enhanced in aRGCs. To test this idea,
we stained retinas with antibodies spe-
cific to phosphorylated-Raptor (pRaptor)
and phosphorylated-Rictor (pRictor),
which are mTORC1- and mTORC2-spe-
cific signaling components, respectively.
pRaptor was concentrated in aRGCs,
whereas pRictor was present at low
levels in non-aRGCs and barely detect-
able in aRGCs (Figures 3C and 3D).
Thus, mTORC1 is active in aRGCs.We then asked whether aRGCs express other genes that
could play roles in their selective survival and regeneration.
In initial studies, we detected expression of OPN (gene symbol
Spp1, for secreted phosphoprotein-1) in large RGCs in
adult retina (M. Yamagata and J.R.S, unpublished data). We
selected this candidate for further analysis because OPN
is expressed by a subset of RGCs in rats (Ju et al., 2000),
can enhance mTOR activity (Ahmed and Kundu, 2010), and
has been implicated in injury responses of other neuronal
types (see Discussion). Immunostaining in the Kcng4-YFP
line revealed that >90% of aRGCs were OPN+, and 84% of
OPN+ RGCs were aRGCs (Figures 3E and 3F). Likewise,
OPN and neurofilament SMI32 staining overlapped by >90%
(Figure S1B).
Figure 2. Selective Regeneration of aRGCs
after Axotomy
(A) Sections from control retina and a retina
infected 2 weeks previously with AAV-shPTEN.
Sections were stained with anti-pS6 and Tuj1.
PTEN knockdown leads to increased mTOR
signaling, revealed by increased levels of pS6. The
scale bar represents 20 mm.
(B) Sections from optic nerves of Kcng4-YFP,
TYW3, and HB9-GFP mice at 14 dpc and 28 days
after injection of AAV-shPTEN. *Lesion site. The
scale bar represents 200 mm.
(C) Section from Kcng4-YFP mouse, as in (B)
but injected with CTB to label all regenerated
axons. All CTB-positive axons are YFP+ aRGCs.
The scale bar represents 200 mm.
(D) Number of labeled regenerating axons 0.5 mm
distal to the lesion site at 14 dpc, based on counts
from sections such as those shown in (C), mean ±
SD, n = 3 to 5 optic nerves per type. *p < 0.05
(two-ANOVA with Bonferroni posttests).
See also Figure S2.To assess whether OPN regulates mTOR activity in the retina,
we used AAV-mediated gene transfer to express OPN in multiple
RGC subtypes. More than 60% of RGCs were strongly OPN+ in
optimally infected areas 2 weeks after infection, and levels of
pS6 were high in 60% of OPN-rich RGCs (Figures 3G and
3H). Because aRGCs constitute only 6%of RCGs, OPN is clearly
able to stimulate mTOR signaling in non-aRGCs We also used
OPN null mutant mice (OPN/) to ask whether the high mTOR
levels of aRGCs require expression of OPN. Levels of pS6 in
aRGCs did not differ detectably between controls and OPN/
mice (Figures 3I and 3J). Thus, OPN stimulates mTOR activity
but is presumably not the only factor that maintains high levels
of mTOR activity in aRGCs.
OPN Promotes RGC Growth of Non-aRGCs
Before assessing the ability of OPN to affect regeneration,
we investigated its role in the normal development of aRGCs.
We found that the difference in size between aRGC and non-
aRGC somata arose during the first postnatal week, whereas
OPN was not detectable in RGCs until the second postnatal
week (Figures 4A and 4B). These results suggested that OPN
is dispensable for the initial growth of RGCs. Consistent with
this idea, we found no significant difference in size between con-
trol and OPN/ aRGCs during the period of peak growth or in
adulthood (Figure S3A and data not shown). Moreover, the ma-
jority of RGCs were rich in pS6 during the first postnatal week,
and pS6 immunoreactivity did not become restricted to aRGCs
until the third postnatal week (Park et al., 2008). Thus, neither
selective mTOR signaling nor selective expression of OPN is
required for aRGCs to reach their normal size.
We also asked whether OPN can promote growth of RGCs in
adults using AAV-mediated gene transfer of OPN, as describedNeuron 85, 1244–1256above. RGC soma size (measured by
area in sections) increased by 30%
over controls 4 weeks after the introduc-
tion of OPN to a broad range of RGCtypes using Thy1-cre mice (Figures 4C and 4D). Analysis
with subtype-specific markers indicated that small W3-RGCs
were affected disproportionately (80% increase in area),
whereas the size of aRGCs did not increase in the presence
of supernormal levels of OPN (Figures 4E and S3B); this is
consistent with the presence of additional growth-promoting
factors in these neurons. Together, these results indicate that
OPN does not play an essential role in the development of
aRGCs but can elicit RGC growth and mTOR signaling in adult
retina.
OPN plus IGF-1 Promotes Axonal Regeneration
To determine whether OPN could promote axonal regeneration
following nerve injury, we used the optic nerve crush protocol
described above but infected retinal cells with AAV expressing
OPN instead of shPTEN. Immunostaining showed expression
of OPN in 80% of RGCs in injured retina (data not shown),
but regeneration was not significantly more effective in its
presence than in control retinas (Figures 5A and 5B). We
therefore combined AAV-OPN administration with intravitreal
injection of a growth factor. We chose IGF-1 because it has
neuroprotective and regeneration-promoting abilities in other
contexts (Dupraz et al., 2013; Hollis et al., 2009) and because
its receptor, IGF1R, is expressed by RGCs (Bu et al., 2013;
Tagami et al., 2009; and see below). IGF-1 alone had no
detectable effect on regeneration, but the combination pro-
moted regeneration as effectively as shPTEN (Figures 5A and
5B). In some cases, axons regenerated and extended more
than 2 mm (Figure S4A). OPN and IGF-1 promoted RGC sur-
vival to a modest extent (Figures S5A and S5B), but the effect
on survival was insufficient to account for the effect on axonal
regeneration., March 18, 2015 ª2015 Elsevier Inc. 1247
Figure 3. Selective mTOR Activity and OPN Expression in aRGCs
(A and B) Section of Kcng4-YFP retina labeled with antibodies to pS6 plus YFP (A) and quantification of their overlap (B).
(C and D) Sections of Kcng4-YFP retina labeled with antibodies to pRaptor (C) or pRictor (D) plus YFP.
(E and F) Section of Kcng4-YFP retina labeled with antibodies to OPN and YFP (E) and quantification of their overlap (F).
(G andH) Section of control retina (top) and retina infected with AAV-OPN (bottom) 2weeks previously, labeled with antibodies to OPN and pS6 (G). (H) Fraction of
OPN+ and pS6+ cells in both conditions.
(I and J) Section of Kcng4-YFP;OPN/ retina labeled with antibodies to pS6 and YFP (I) and fraction of YFP+ cells that were pS6+ (J).
n = 3 retinas per condition. The scale bars represent 50 mm.We then tested the relationship of OPN, IGF-1, and mTOR
activation as promoters of regeneration. IGF-1 on its own
had no detectable effect of mTOR signaling in RGCs
following axotomy, but expression of OPN, with or without
IGF-1 enhanced mTOR signaling, after axotomy, as it did in
normal retinas (Figures S6A and S6B). Moreover, rapamycin,
a potent and specific inhibitor of mTOR (Laplante and Sabatini,
2012), blocked axonal regeneration promoted by OPN plus
IGF-1 (Figures 5C and 5D) as well as the OPN-induced in-
crease in pS6 levels (Figure S6C) with minimal effects on1248 Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc.neuronal survival (Figure S5C). Conversely, regeneration
promoted by shPTEN is affected little if at all in OPN/
mice (data not shown). These data place mTOR signaling
downstream of OPN in a molecular pathway that promotes
regeneration.
We also tested the combination of OPN and brain-derived
neurotrophic factor (BDNF), because BDNF promotes RGC
branching, and its receptor, TrkB, is expressed by RGCs (Cui
et al., 2002; Sawai et al., 1996). Like IGF-1, BDNFwas ineffective
on its own at promoting regeneration and had amodest effect on
Figure 4. Role of OPN in Developing Retina
(A) Sections from retinas from TYW7mice of indicated ages stained with antibodies to YFP and OPN. TYW7 labels OFF aRGCs (Kim et al., 2010; B. Krieger, M.Q,
X.D., J.R.S., and M. Meister, unpublished data). OPN+ YFP cells are presumably ON aRGCs. Staining is absent in retinas from OPN/ mice. The scale bar
represents 50 mm.
(B) Soma sizes of developing aRGCs and non-aRGCs and OPN levels in aRGCs in developing retina. OPN levels were measured from sections such as those in
(A), as described in Experimental Procedures.
(C) Retinas from Thy1-cre mice infected 4 weeks previously with Cre-dependent AAV-YFP, with or without Cre-dependent AAV-OPN. Sections were labeled with
antibodies to YFP and OPN. The bar represents 20 mm.
(D) RGC soma area, calculated from images such as those in (C).
(E) Soma size increase of W3-RGCs and aRGCs, measured from sections such as those in Figure S3B. **p < 0.01.
See also Figure S3.survival. However, OPN plus BDNF stimulated regeneration to a
similar extent as OPN plus IGF-1 (Figures 5E, 5F, and S5B). Thus
the stimulatory role of IGF-1 was not unique, and OPN can pro-
mote substantial axon regeneration when paired with growth
factors.OPN plus IGF-1 Promotes Selective Regeneration of
aRGCs
We expected that administration of OPN plus IGF-1 tomost or all
RGCs would promote regeneration in multiple RGC types. To
test this idea, we introduced AAV-OPN and IGF-1 intravitreallyNeuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc. 1249
Figure 5. OPN Promotes Regeneration of
Axotomized RGCs
(A) Sections of optic nerves at 14 dpc. Retinas
were untreated, infected with AAV-OPN, injected
with IGF-1 or BDNF, or both infected and injected.
(B) Numbers of regenerating fibers at indicated
distances from lesion site, measured from sec-
tions such as those in (A).
(C) Sections of optic nerves from Kcng4-YFP mice
injected with (AAV-OPN+IGF-1) with or without
rapamycin.
(D) Numbers of regenerating fibers, measured
from sections such as those in (C) and Figure S5C.
n = 3 to 5 optic nerves per condition.
(E) Sections of optic nerves from Kcng4-YFP mice
injected with BDNF with or without AAV-OPN.
(F) Numbers of regenerating fibers measured from
sections such as those in (E).
The scale bars for (A), (C), and (E) represent
200 mm. *p < 0.05.
See also Figures S4 and S5.in Kcng4-YFP, HB9-GFP, and TYW3 mice to label aRGCs,
ooDSGCs, and W3-RGCs, respectively. Surprisingly, using pro-
tocols and criteria described above (Figure 2), we found that
nearly all regenerating axons arose from aRGCs (Figures 6A
and 6B).
The ability to selectively target aRGCs provides an opportunity
to ask whether the delivery of OPN directly to aRGCs promote
regeneration. To that end, we used an AAV in which expression
of OPN was Cre dependent and limited overexpression to
aRGCs by infecting retinas of Kcng4-YFP mice. aRGC-specific
expression of OPN promoted aRGC regeneration after nerve
crush (Figures 6C and 6D).
Selective IGF1R Expression and mTOR Signaling in
Axotomized aRGCs
The result that AAV-OPN and IGF-1 are insufficient to promote
regeneration of other RGC subtypes to which they are delivered
implies that aRGCs differ from non-a-RGCs in some quality that
enhances their regenerative responses after injury. The restric-
tion of shPTEN-induced regeneration to aRGCs (Figure 2)
leads to the same conclusion. The difference could be in the1250 Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc.ability of RGC subtypes to respond to
IGF-1, to upregulate mTOR signaling, or
to respond appropriately to IGF-1- and
mTOR-initiated signals. As a first step
in distinguishing these alternatives, we
compared levels of the IGF-1 recep-
tor (IGF1R) in aRGCs and non-aRGCs.
IGF1R was selectively expressed in
aRGCs in both control adult retinas and
in retinas 3 and 7 dpc, although some
expression in non-aRGCs andMu¨ller glial
cells was observed after axotomy (Fig-
ure 7A). TrkB showed a similar expres-
sion pattern, although the expression
was less selective and the neuropil wasalso intensely stained (Figure S7). Thus, one factor contributing
to selective responsiveness of aRGCs to OPN plus growth
factors is selective expression of the growth factor receptors.
We also compared levels of mTOR signaling in axotomized
aRGCs and non-aRGCs, using pS6 as a marker. Levels of pS6
fell dramatically in RGCs following axotomy, as shown previously
(Park et al., 2008), and introduction of shPTEN or OPN plus IGF-1
restored its levels. These treatments were 9-fold and 3-foldmore
effective, respectively, in increasing pS6 levels in axotomized
aRGCs than in neighboring non-aRGCs (Figures 7B and 7E).
Moreover, even though aRGCs constituted only 20% of surviv-
ing RGCs at 14 dpc, they accounted for 90% of pS6-rich
RGCs following shPTEN treatment and 60% of pS6-RGCs af-
ter OPN plus IGF-1 treatment. As in control retinas (Figure 3A),
levels of pRaptor paralleled those of pS6: aRGCs accounted
for >90% of pRaptor-rich RGCs after either shPTEN treatment
or OPN plus IGF-1 administration (Figure 7C and data not
shown). In contrast, the levels of pRictor were low, with <5%
of total aRGCs being pRictor-positive. Moreover, the pRictor
level did not differ detectably between aRGCs and non-aRGCs
and did not change detectably following shPTEN treatment or
Figure 6. Osteopontin Promotes Selective
Regeneration of aRGCs
(A) Sections of optic nerves of Kcng4-YFP, TYW3,
and HB9-GFP mice at 14 dpc treated with AAV-
OPN and IGF-1 and injected with CTB at 12 dpc.
(Right) Region boxed at top left.
(B) Numbers of regenerating fibers 0.5 mm from
lesion site from sections such as those in (F). n = 3
or 4 optic nerves per type. *p < 0.05.
(C) Section of optic nerves from Kcng4-YFP
mice injected with Cre-dependent AAV-OPN
plus IGF-1.
(D) Numbers of regenerating fibers 0.5 mm from
lesion sites, measured from sections such as
those in (C). p < 0.05 (two-ANOVA with Bonferroni
posttests).
See also Figure S6.OPN plus IGF-1 administration (Figure 7D). (The ability of the
pRictor antibody to detect mTORC2 signaling is demonstrated
by staining of non-neuronal cells in injured but not intact retina;
compare Figures 3D and 7D.) Thus, a second property of aRGCs
that can help account for their ability to regenerate is their ability
to maintain or restore mTORC1 levels after axotomy.
DISCUSSION
After damage to the optic nerve, few RGCs survive, and even
fewer can be coaxed to extend new axons (Aguayo et al.,
1991; Liu et al., 2011). Using markers of 11 RGC subtypes, we
found that limited survival and regeneration do not reflect uni-
formly low vigor of many subtypes; instead, they result from se-
lective survival and regeneration of specific subtypes. We then
analyzed factors that promote regeneration of those RGCs that
survive and identified OPN as a promoter of RGC growth and
regeneration. Together, our results provide new insights into
both the cellular and molecular bases of axon regeneration in
the mammalian CNS.
Selective Survival and Regeneration of aRGCs
We found dramatic differences among RGC subtypes in
their ability to survive axotomy. Some populations, such as
ooDSGCs, are almost completely eliminated within 2 weeks,
whereas most aRGCs and M1-RGCs survive. These results
are consistent with previous reports that M1-RGCs preferen-
tially survive axotomy in rats and that alpha-like RGCs selec-
tively regenerate in cats (Pe´rez de Sevilla Mu¨ller et al., 2014;
Robinson and Madison, 2004; Watanabe et al., 1993; Wata-
nabe and Fukuda, 2002; Watanabe et al., 1995). DifferentialNeuron 85, 1244–1256susceptibility to injury has also been re-
ported in a mouse model of glaucoma,
although the subtypes affected were
not molecularly identified (Della Santina
et al., 2013). As a consequence of selec-
tive survival, the repertoire of visual fea-
tures that the retina could potentially
report to the brain is fundamentally
altered (Figure 1D), a change that willneed to be taken into account if efforts to promote regeneration
of RGC survivors succeed.
Among surviving RGCs, the ability to regenerate is specific to
aRGCs, an evolutionarily conserved RGC type characterized by
large somata, smooth dendrites, high levels of neurofilaments,
and large receptive fields (Berson, 2008; Peichl, 1991). aRGCs
comprise 6% of all RGCs in intact retina and 25% of the
RGCs that survive axotomy but give rise to >90% of the axons
that extend >0.5 mm beyond the site of nerve crush following
downregulation of PTEN. In that aRGCs and non-aRGCs are
intermingled in the retina, and their axons are intermingled in
the optic nerve, it is almost certain that the differences in their
regenerative abilities reflect intrinsic differences rather than
differences in their environments.
One caveat to the conclusion that aRGCs regenerate selec-
tively is that we tested only two regeneration-promoting treat-
ments, PTEN knockdown and OPN plus a growth factor. It will
be important to ask whether other interventions, such as deletion
of suppressor of cytokine signaling 3 or provoking an inflamma-
tory response (Benowitz and Popovich, 2011; Morgan-Warren
et al., 2013; Park et al., 2008; Smith et al., 2009; Sun et al.,
2011; Watkins et al., 2013), can promote regeneration of addi-
tional RGC subtypes.
OPN as a Promoter of Axon Regeneration
OPN promotes RGC regeneration when introduced in combina-
tion with either IGF-1 or BDNF, neither of which promotes signif-
icant regeneration on its own. OPN is a secreted, glycosylated
phosphoprotein; it was discovered as a component of bone
matrix but has since been shown to be synthesized by many
cell types and to affect multiple cellular processes, including, March 18, 2015 ª2015 Elsevier Inc. 1251
Figure 7. Selective Expression of IGF1R and
Activation of mTOR Signaling in Axotom-
ized aRGCs
(A) IGF1R expression in aRGCs (labeled with OPN)
in control retinas, 3 and 7 dpc.
(B–D) Sections from mice injected with control
vector, AAV-shPTEN, or AAV-OPN plus IGF-1.
Optic nerves were crushed 14 days later and
retinas analyzed 14 dpc with anti-pS6 (B), anti-
pRaptor (C), or anti-pRictor (D). The scale bars
represent 50 mm.
(E) Fraction of aRGC and other RGCs (YFP+ and
YFP, respectively, in Kcng4-YFP) that are pS6+,
from sections such as those in (B). n = 4 to 6 retinas
per treatment.
(F) Model showing pathways by which PTEN
knockdown or exogenous OPN expression could
promote regeneration. a, b, and c indicate steps
at which differences between aRGC and non-
aRGCs could affect their regenerative abilities.
Results in (A–E) implicate steps a and b as critical
differences (see Discussion).
See also Figure S7.
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adhesion, proliferation, and survival (Kahles et al., 2014; Kaza-
necki et al., 2007; Wang and Denhardt, 2008). It is expressed
by subsets of neurons as well as several classes of glial cells,
including Schwann cells, Mu¨ller glia, and microglia. Levels are
affected by neural injury in several systems, and OPN is reported
to exert both pro- and anti-inflammatory roles that can promote
neuronal survival and regeneration (Carecchio and Comi, 2011;
Chidlow et al., 2008; Del Rı´o et al., 2011; Hashimoto et al.,
2007; Misawa et al., 2012; Wright et al., 2014). In most cases,
these effects have been ascribed to depots in glial cells; for
OPN-stimulated regeneration of injured motor axons, elegant
transplantation experiments have demonstrated that this is the
case (Wright et al., 2014). In the retina, in contrast, directed de-
livery reveals that neuron-derived OPN promotes regeneration.
OPN may be useful for promoting regeneration for several
reasons. First, PTEN is a tumor suppressor. Whereas OPN,
like PTEN knockdown, acts in part by elevating mTOR, PTEN
inhibition also activates many additional pathways that likely
contribute to its tumor suppressor activity. OPNmay circumvent
this potentially dangerous activity. Second, soluble protein ther-
apeutics are clearly promising for treatment of a variety of neural
injuries and neurological diseases (Thoenen and Sendtner,
2002). In other systems, OPN acts as an extracellular cytokine
(Kahles et al., 2014). Therefore, a soluble form of OPN, together
with a growth factor, might represent a therapeutic method of
transiently activating regenerative ability in mature neurons.
Growth-Promoting Capabilities of aRGCs
Regeneration promoted by OPN plus IGF-1 or shPTEN is
restricted to aRGCs. This surprising result raises two questions.
First, why are endogenous OPN and mTOR, both of which are
enriched in adult aRGCs, insufficient to promote their regenera-
tion? Second, why is regeneration restricted to aRGCs even
when OPN plus IGF-1 or shPTEN is supplied to most RGCs?
One answer to the first question is that mTOR signaling de-
creases dramatically following axon damage (Park et al., 2008).
We hypothesized that OPN might also decrease following
axotomy, but we detected no striking changes in OPN levels
by immunohistochemistry or in OPN mRNA levels by RT-PCR
(data not shown). However, our immunohistochemical methods
are non-quantitative, and decreases in OPN mRNA abundance
in RGCs would have been masked by known increases in micro-
glia (Chidlow et al., 2008). Moreover, OPN is heterogeneous in
several respects: there are several alternatively spliced isoforms
(at least in humans), many forms of post-translational modifica-
tion, and an alternative translation product that remains intracel-
lular and mediates activities distinct from those of the secreted
isoform (Gimba and Tilli, 2013; Inoue and Shinohara, 2011; Kaza-
necki et al., 2007). It remains to be determined which forms
promote regeneration and whether the active forms, which
may be a small fraction of the total, are affected by axotomy.
In considering the second question, we note that at least two
signaling pathways are activated by the interventions we have
assayed here (Figure 7F). The first is mTOR signaling, as indi-
cated by the sensitivity of PTEN small hairpin RNA and OPN-
induced regeneration to the mTOR-specific blocker rapamycin
(Park et al., 2008) (‘‘a’’ in Figure 7F). For reasons we do not
yet understand, OPN upregulates mTOR signaling selectivelyin aRGCs following axotomy, even though it can upregulate
mTOR signaling in most RGCs in uninjured retina.
mTOR signaling alone is insufficient for robust regeneration,
however. PTEN regulates several pathways other than mTOR
(Hill and Wu, 2009; Manning and Cantley, 2007; Morgan-Warren
et al., 2013) and interventions that more selectively upregulate
mTOR signaling, such as deletion of TSC1, are significantly
less effective in eliciting regeneration than downregulation of
PTEN (Park et al., 2008). Likewise, OPN can upregulate mTOR
signaling in the presence or absence of a growth factor but
does not induce regeneration unless accompanied by a growth
factor. Thus, mTOR-dependent and mTOR-independent path-
waysmust be co-activated for optimal regeneration. We suggest
that IGF-1, which does not detectably enhance mTOR signaling,
activates the mTOR-independent pathway (‘‘b’’ in Figure 7F).
Selective activation of this pathway in aRGCs is likely based
on the selective expression of IGF1R by aRGCs. Other salient
differences between aRGCs and non-aRGCs may well exist,
for example at later steps in the signaling pathway (‘‘c’’ in
Figure 7F). Molecular comparison of subtypes refractory and
susceptible to the effects of injury will be a promising approach
for identifying these and other factors that promote survival and
regeneration.
EXPERIMENTAL PROCEDURES
Animals
OPN mutant mice were produced by inserting CreER into the translation start
codon of the spp1 gene using lambda phage-mediated recombineering (Chan
et al., 2007), followed by homologous recombination in embryonic stem cells.
Chimeras were produced by the Harvard University Genome Modification Fa-
cility. High-percentage chimeras transmitting the knockin allele were bred to
animals expressing FLP recombinase from the b-actin promoter (Rodrı´guez
et al., 2000) to remove the PGK-NEO cassette. Primers used for genotyping
OPNCreER are OPN Common Forward Primer (TTGGTGGTGATCTAGTGGTG
CCAA), CreER Reverse Primer (CATCGACCGGTAATGCAGGCAAAT), and
OPN wild-type Reverse Primer (CAAGGAAATGCGTGTGAGTGTGCT). The
primers amplify fragments of 500 bp for the knockin allele and 225 bp for the
wild-type allele. Insertion of CreER led to generation of a null allele (Figure 4A
and data not shown). However, we detected very low levels of CreER expres-
sion and activity in this line, so it was not useful for marking OPN-expressing
cells.
HB9-GFP transgenic mice (Trenholm et al., 2011) were obtained from K.
Eggan (Stem Cell and Regenerative Biology Department, Harvard University),
and Thy1-cre transgenic mice (Dewachter et al., 2002) were obtained from
Jackson Laboratories. Other lines were generated and characterized in our
laboratory as described previously: Kcng4-Cre (Duan et al.,2014), TWY3-
YFP (Kim et al., 2010; Zhang et al., 2012), TWY7-YFP (Kim et al., 2010), and
Thy1-STOP-YFP (Buffelli et al., 2003). Mice were maintained on a C57/BL6
background and experiments were done according to protocols approved
by both the Harvard University Standing Committee on the Use of Animals in
Research and Teaching and IACUC at Boston Children’s Hospital.
Gene Transfer and Surgical Methods
A cDNA encoding OPN was cloned from a mouse retina cDNA library (Kay
et al., 2011) and inserted into AAV plasmids for ubiquitous or Cre-dependent
expression (Cardin et al., 2009). The coding sequence corresponds to that in
accession number BC020355 (NCBI-Nucleotide). AAV-U6-shPTEN-CMV-
mCherry was modified from a previously characterized vector AAV-U6-
shPTEN-CMV-GFP (Zukor et al., 2013) by changing the fluorescent protein.
The targeting sequence was AGGTGAAGATATATTCCTCCAA. AAV serotype
2/2 was produced at Boston Children’s Hospital Viral Core. AAV2 was titered
to >1 3 1012 genome copies per milliliter.Neuron 85, 1244–1256, March 18, 2015 ª2015 Elsevier Inc. 1253
Detailed surgical methodswere described by Park et al. (2008). For injection,
adult animals were anesthetized with ketamine/xylazine (100/10 mg/kg). AAV
(3 ml) was injected intravitreally with a fine glass pipette. Optic nerves were
crushed with a pair of Dumont #5 forceps (Roboz) 2 weeks after injection.
IGF-1 or BDNF (1 ml, 1 mg/ml, Peprotech) was injected into the vitreal space
of the eye at 0 and 7 dpc. One microliter of Alexa-conjugated CTB568 or
647 (Invitrogen) was injected intravitreally 2 to 3 days before euthanasia to
label all regenerating axons. Rapamycin (6 mg/kg, LC Laboratories) was deliv-
ered intraperitoneally every 2 days from the time of AAV injection.
Histology
Anesthetized mice were transcardially perfused with 4% paraformaldehyde
(PFA). Eyes and optic nerves were dissected out and post-fixed in 4% PFA
at 4C overnight. For frozen sections, tissues were immersed in 30% sucrose
for 2 days before sectioning in a cryostat (20 mm for retina, 10 mm for optic
nerve). For some experiments, eyes were fixed in 4%PFA at 4Cby immersion
for 30 to 60 min, immediately after the mice were sacrificed by a lethal over-
dose of anesthesia.
For immunohistochemistry, sections were incubated in PBS with 3%
donkey serum and 0.3% Triton X-100 for blocking, followed by primary anti-
bodies overnight at 4C and secondary antibodies for 2 hr at room temper-
ature. Whole mounts were incubated in PBS with 5% donkey serum and 0.5%
Triton X-100 for blocking, followed by primary antibodies forR48 hr at 4C and
secondary antibodies for R16 hr at 4C. Finally, sections were washed with
PBS and mounted in Vectashield (Vectorlabs).
Primary antibodies used were rabbit anti-GFP (1:1,000, Millipore), chicken
anti-GFP (1:500, Abcam), rabbit anti-red fluorescent protein (1:500, Abcam),
rabbit anti-CART (1:2,500, Phoenix Peptide), rabbit anti-melanopsin (1:1,000,
gift from I. Provencio, University of Virginia), rabbit anti-phosphorylated S6
Ser235/236 (1:200, Cell Signaling Technology), mouse anti-neurofilament
(SMI32, 1:1,000, Convance), rabbit anti-IGF1R (1:1,000, Sigma), goat anti-
mouse TrkB (1:500, R&D Systems), rabbit anti-phosphorylated-Raptor
(Ser792) (1:200, Cell Signaling Technology), rabbit anti-phosphorylated-Rictor
(Thr1135) (1:200, Cell Signaling Technology), and goat anti-OPN (1:1,000, R&D
Systems). Nuclei were labeled with NeuroTrace Nissl 435/455 (1:1000, Invitro-
gen). Secondary antibodies were conjugated to DyLight 649 (Jackson Immu-
noResearch), Alexa Fluor 568, or Alexa Fluor 488 (Invitrogen) and usedat 1:500.
Imaging and Quantification
For whole mounts of retinas, at least eight areas (0.5 3 0.5 mm) across
the whole retinas were imaged with a standard epi-fluorescence microscope
(Nikon) focusing on the retinal ganglion layer. Cells were counted, and the
counts obtained from all areas were averaged to generate a single value for
each retina.
For retina sections, images were taken with a confocal microscope
(Olympus FV1000 or Zeiss LSM-710) using 440/488–515/568 and 647 lasers
with a step size of 0.5 mmand a 403 (NA 1.3) lens. Images were analyzed using
ImageJ software (NIH). One field from at least eight sections per sample were
imaged and analyzed. The numbers from all sections were averaged to
generate a single value for each retina.
For soma size measurement, Z stacks were projected onto a single plane,
and the largest area was measured with ImageJ. To measure level of immuno-
reactivity, slides were stained, mounted, and imaged in parallel, and the
signals were imaged within a linear range. Fluorescent intensity wasmeasured
in ImageJ to indicate the relative expression level.
For nerve sections, regenerating axons were identified and counted as
described previously (Park et al., 2008). In analyzing YFP+ axons, signals from
fluorescent or autofluorescent tissue debris was excluded.
Only contrast and brightness were adjusted for all images. Caution was
taken not to oversaturate the images, and only brightly stained cells were
counted when positive staining was to be identified.
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